Study Title and Description
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Key Questions Addressed
|7||Key Question 7. What is the effectiveness of currently recommended antiviral treatments in achieving a SVR in patients with HCV infection?|
|8||Key Question 8. What are the harms of currently recommended antiviral treatments?|
Primary Publication Information
|Title||Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.|
|Author||Feld JJ., Kowdley KV., Coakley E., Sigal S., Nelson DR., Crawford D., Weiland O., Aguilar H., Xiong J., Pilot-Matias T., DaSilva-Tillmann B., Larsen L., Podsadecki T., Bernstein B.|
|Country||From the Toronto Centre for Liver Disease, University of Toronto, Toronto (J.J.F.); Digestive Disease Institute, Virginia Mason Medical Center, Seattle (K.V.K.); AbbVie, North Chicago, IL (E.C., J.X., T.P.-M., B.D.-T., L.L., T.P., B.B.); New York University School of Medicine, New York (S.S.); University of Florida College of Medicine, Gainesville (D.R.N.); Gallipoli Medical Research Foundation and School of Medicine, University of Queensland, Brisbane, Australia (D.C.); Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm (O.W.); and Louisiana Research Center, Shreveport (H.A.).|
Pubmed ID: 24720703
Secondary Publication Information
There are currently no secondary publications defined for this study.
Extraction Form: Key Questions 1-9
Results & Comparisons
No Results found.